Metrics to compare | RUBI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRUBIPeersSector | |
|---|---|---|---|---|
P/E Ratio | 94.5x | 32.1x | −0.4x | |
PEG Ratio | 1.24 | 0.70 | 0.00 | |
Price/Book | 18.1x | 2.3x | 2.6x | |
Price / LTM Sales | 13.3x | 3.6x | 3.0x | |
Upside (Analyst Target) | −17.0% | 5.2% | 55.7% | |
Fair Value Upside | Unlock | 2.1% | 8.1% | Unlock |
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.